drugset / Trial / NCT03461406
A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants
RandomizedParallel-groupSingle-blindTreatment
Summary
The objective of the study is to evaluate if FS Grifols is non-inferior to EVICEL® in terms of the percentage of participants achieving hemostasis at the target bleeding site (TBS) by 4 minutes (T4) from the start of treatment application (TStart) with no occurrence of rebleeding until the completion of the surgical closure by layers of the exposed surgical field containing the TBS (TClosure).
Timeline
- Start
- 2019-01-18
- Primary completion
- 2022-04-15
- Completion
- 2022-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fibrin Sealant Grifols | Protein / enzyme biologic | 80 mg/ml | Topical |
| Subject | Fibrin Sealant Grifols | Protein / enzyme biologic | 500 iu | Topical |
| Comparator | Fibrinogen Concentrate Human | Protein / enzyme biologic | — | Topical |
Indications
No indication recorded.